SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump For President

The price of TRUMP CRYPTO is volatile as traders debate its potential, with some citing exhaustion of sellers while others point to corruption and call it a scam. Community members are expressing strong opinions, with some predicting a short squeeze and others anticipating a crash. Broader market factors and political events seem to be influencing the coin's movements.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors react to its new NFL partnership, with some questioning the long-term impact and target audience fit, while others see potential for growth, especially with college-aged women. Community members are actively debating the significance of the deal and the company's overall direction, as well as the impact of analyst ratings. There's also discussion around potential manipulation and short squeezes in the stock.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending due to discussions around a potential acquisition deal falling through, leading to price volatility. The community is debating the implications of this failed deal, particularly regarding the company's future prospects and potential government support, in light of its position in the antimony market amid ongoing concerns about supply chain independence from China. Traders are also actively discussing technical analysis, potential entry points, and the stock's overall long-term value.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending due to its entrance into the AI chip market, highlighted by the launch of new AI200 and AI250 chips aimed at data centers, positioning it as a competitor to Nvidia and AMD. Community discussions revolve around the potential impact of these chips, particularly their power efficiency and customer base, with some analysts expressing skepticism about revenue projections. The move signifies Qualcomm's diversification beyond mobile chips into the growing AI infrastructure sector.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending due to a pause in two Phase 3 trials of its gene-editing therapy, nex-z, following a patient hospitalization with liver problems, causing a significant stock drop. The community is debating the severity of the setback, with some viewing it as a buying opportunity due to the company's long-term potential and strong pipeline, while others express concern about the program's future. Discussions also include the impact on the broader gene-editing sector and comparisons to similar situations with other companies.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its potential role in the AI revolution, particularly highlighting its network infrastructure and a recent expansion of its Internet On-Demand service. Community members are weighing in on the company's prospects, with many focused on upcoming earnings and potential government contracts. There's considerable discussion around Lumen's Palantir partnership and speculation about further upside.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community rallies around a potential breakout, fueled by the optimistic "WAGMI" (We Are All Gonna Make It) sentiment. Discussions revolve around key resistance levels and the possibility of a Solana ETF, while some traders are also watching meme coins built on Solana, such as SLAP and WAGMI.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending as community members highlight staking rewards and IRL partnerships, including MMA fighter Karolina Arm. The community emphasizes the project's strong team and growing recognition within the crypto space. Discussions also focus on $SLAP's potential as a meme coin with real-world utility.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels ($UUUU) is trending as investors discuss its potential role in securing a U.S.-based rare earth supply chain, particularly in light of geopolitical tensions with China and a recent joint venture in Australia. The community is also closely watching for potential government contracts and discussing high call option activity, suggesting possible insider knowledge or a significant upcoming catalyst. Some traders express concerns about stock dilution and the company's path to profitability.

Project Nema is a research initiative enhancing AI memory and companionship by integrating the C. elegans neural connectome with a large language model (LLM). The LLM translates human language to interact with the worm's simulated brain, addressing LLMs' lack of persistent emotional or psychological states beyond context windows. This creates a stable, evolving neural state that retains history across sessions. For example, user inputs like "good morning Nema" fetch state and history for processing. Utilities include companionship, where Nema acts as the LLM's "soul" for long-term personality building, and dynamic adaptation mimicking life. It also aims to boost LLM outputs via extended memory. The project involves user management and visualizations.

NEMA LAB

NEMA is trending as discussions highlight its AI utility and migration from the WORM project, with community members emphasizing its potential and unique technology. The migration is seen as a catalyst, with many believing NEMA can surpass WORM's previous market cap due to its added utility and 'intelligence'. It's part of a broader conversation around AI-driven crypto projects on the SOL network.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 12, 2025 - BHVN

Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 12, 2025 - BHVN Faruqi & Faruqi Reminds Biohaven Investors of the Pending...

Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi & Korsinsky

Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi & Korsinsky Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi...

Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related to R&amp;D deals and milestone payments.&nbsp;The expense is set to shave&nbsp;off about $0.26 off its per-share earnings, both on a GAAP and adjusted basis.The update adds to investor caution following the FDA’s recent signal report published on June 30, which named Biogen’s Alzheimer’s treatment Leqembi as one of several drugs flagged for potential post-marketing safety concerns.&nbsp;The report, compiled from the FDA’s FAERS database, represents a push for increased transparency around adverse event reporting.Analysts at RBC Capital said they do not anticipate major regulatory fallout, noting that the data was already publicly available and the risks broadly acknowledged.&nbsp;However, they said the FDA’s move could still create some sentiment overhang for Biogen and other named firms, including Sarepta, Alkermes, Biohaven, Xenon, and Argenx.<a href="https://stocktwits.com/symbol/BIIB">Biogen’s</a> newly itemized R&amp;D charges follow its Q1 decision to present such costs as a separate line item on its income statement.&nbsp;The company stated that these typically include expenses from licensing deals and asset acquisitions, which are accounted for as in-process research and development.Meanwhile, Biogen is advancing its drug pipeline, beginning a Phase 3 study with felzartamab, which can treat a kidney condition known as primary membranous nephropathy.The trial, dubbed Prominent, began dosing patients late last month and will enroll about 180 adults.On Stocktwits, retail sentiment for Biogen was ‘bullish’ amid ‘low’ message volume.Biogen’s stock has declined 13.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Equity

Biohaven Pharma stock tumbles after withdrawal of Dazluma application in EU

Investing.com -- Biohaven Pharma (NYSE: BHVN) shares fell sharply by as much as 21% as the company withdrew its marketing authorization application for Dazluma in Europe, intended to treat spinocerebellar ataxia genotype 3 (SCA3). The stock's downturn followed a brief trading halt due to volatility.

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Deutsche Bank initiates coverage of biopharma stocks, sees 'modest recovery'

Investing.com -- Deutsche Bank initiated coverage on 11 U.S. biopharma stocks in a note Tuesday, assigning Buy ratings to eight companies and Hold ratings to three. 

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia Biohaven Announces FDA Acceptance and Priority Review of...

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation P

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective...

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire NEW HAVEN, Conn., Jan. 7, 2025 NEW HAVEN...

Shares of Biohaven (BHVN) gained in morning trade on Tuesday after the company’s director John W. Childs acquired shares worth $1.04 million on Monday.According <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1935979/000193597924000088/xslF345X05/wk-form4_1735646406.xml">to</a> Biohaven’s U.S. Securities and Exchange Commission (SEC) filing, Childs acquired 29,000 shares of the company for the benefit of John W. Childs Revocable Trust, at an average price of $35.9446 apiece, over 3% lower than the current market price of $37.07.Biohaven is a Connecticut-based biopharmaceutical company that focuses on the discovery and development of drugs across therapeutic areas like neuroscience, immunology, and oncology.Earlier this month, the company reported that it achieved essential milestones in the trial of its experimental drug BHV-1300, intended for use in treating a kidney disease. Biohaven also has other trials underway to treat autoimmune diseases.Analysts at RBC Capital raised their price target for the Biohaven stock to $61 from $58 while maintaining an ‘Outperform’ rating, according to TheFly.However, in November, the company’s spinal muscular atrophy (SMA) trial misfired after it failed to achieve its primary endpoint.Reacting to the news of Childs acquiring company shares, Biohaven stock gained over 4% in morning trade on Tuesday, before paring some of the gains.Retail sentiment on Stocktwits entered the ‘bullish’ territory (58/100), with message volume picking up, too.<figure class="image"><img style="aspect-ratio:649/147;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_31_213107_8d3615ce5c.jpg" alt="BHVN stock sentiment" width="649" height="147"><figcaption>BHVN sentiment and message volume December 31, 2024, as of 11:30 am ET | Source: Stocktwits</figcaption></figure>Overall, though, Biohaven’s shares are down nearly 18.5% over the past month, and 13% year-to-date.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/axsome-therapeutics-stock-tumbles-as-alzheimer-studies-reveal-mixed-results/cJOiJFyRki">Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail Sentiment Remains Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of a biopharmaceutical company | Photo by Bernd Weißbrod/picture alliance via Getty Images

Biohaven Stock Surges After Director Acquires Shares Worth Over $1M: Retail Sentiment Turns Bullish

Earlier this month, Biohaven reported achieving important milestones in the trial of its experimental drug BHV-1300, which is intended for use in the treatment of kidney disease.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Will Meta ($META) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Meta Platforms Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.88	--	--	N/A
Q2 '25	-$1.90	-$1.94	-1.99%	MISSED
Q1 '25	-$1.70	-$2.17	-27.62%	MISSED
Q4 '24	-$1.57	-$1.85	-17.47%	MISSED
Q3 '24	-$1.70	-$1.70	0.09%	BEAT

BHVN
Biohaven Pharmaceutical Holding Company Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest BHVN News

BHVNBiohaven Pharmaceutical Holding Company Ltd